Why the study?
Does intracoronary oestrogen attenuate coronary vasoconstriction and reduce endothelin-1 levels in patients undergoing elective coronary angioplasty?
Population
24 consecutive patients scheduled for elective coronary angioplasty
Comparison
Intracoronary treatment with oestrogen vs No intracoronary treatment with oestrogen
Design
RCT, randomized into two groups
Follow-up
15 min after angioplasty
Key result
Intracoronary oestrogen significantly blunted coronary vasoconstriction 15 minutes after angioplasty, attenuating the 29% rise in endothelin-1 levels observed in the control group.
Authors
Loading...
May support intracoronary oestrogen as adjunct in angioplasty; extends RCT evidence on endothelin-1 modulation.
RCT (n=24)
randomized into two groups
Does intracoronary oestrogen attenuate coronary vasoconstriction and reduce endothelin-1 levels in patients undergoing elective coronary angioplasty?
Intracoronary oestrogen administration attenuates post-angioplasty coronary vasoconstriction by reducing endothelin-1 release.
Lee et al. (2002) conducted an RCT in elective coronary angioplasty (n=24). intracoronary oestrogen vs. no intracoronary oestrogen was evaluated on coronary artery diameter at the dilated segments 15 min after dilation. Intracoronary oestrogen significantly blunted coronary vasoconstriction 15 minutes after angioplasty, attenuating the 29% rise in endothelin-1 levels observed in the control group.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: